At baseline, detectable ctDNA and a higher molecular tumor burden were each associated with shorter progression-free survival in both treatment arms. The authors said the pattern was consistent with greater underlying disease burden and intrinsic risk; the observational associations do not show that ctDNA detectability or molecular burden caused the poorer outcomes. The genomic analysis also identified adverse risk features involving MYC, the PI3K–AKT pathway and BRCA or homologous recombination repair genes.

These features characterized an adverse genomic-risk profile among the patients analyzed. PIK3CA and ESR1 status produced an exploratory treatment-informative signal, indicating that their relationship with outcomes differed according to treatment context in the analysis. In separate landmark analyses, on-treatment ctDNA clearance and reductions in molecular tumor burden were associated with favorable subsequent outcomes.

Profiling at the end of treatment identified candidate resistance-associated alterations following bireociclib, including FGFR1, MDM2 and MYC amplifications and activation of the MAPK pathway. These are candidate markers associated with treatment-emergent genomic changes, not definitive resistance biomarkers or evidence of a causal resistance mechanism. Overall, the results indicate that longitudinal ctDNA profiling may provide information for risk stratification, response monitoring and resistance tracking during CDK4/6 inhibitor-based therapy, with the analysis presented as exploratory.

Subject of Research: Longitudinal ctDNA profiling of bireociclib in advanced breast cancer

Article Title: Longitudinal ctDNA profiling reveals genomic risk and molecular response to bireociclib in advanced breast cancer

Article References: Wang, Y., Xu, H., Zhou, Y., Cui, L., Sa, Q., Cheng, H., Gao, R., Zhang, Q., Li, H., Tong, Z., Ouyang, Q., Tan, X., Bai, J., Wang, L., Duan, X., Yang, F., Wang, J., & Xu, B. (2026). Longitudinal ctDNA profiling reveals genomic risk and molecular response to bireociclib in advanced breast cancer. Nature Communications. https://doi.org/10.1038/s41467-026-78782-5

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78782-5

Keywords: ctDNA, bireociclib, advanced breast cancer, BRIGHT-2 trial, genomic risk, molecular response, drug resistance, CDK4/6 inhibition, progression-free survival, PIK3CA, ESR1, MAPK pathway

The central biological argument is that cancer detectability depends on more than tumor volume. The TRACERx study cited by the authors found that the extent to which lung tumors shed circulating tumor DNA is an intrinsic feature of tumor biology, with greater shedding associated with lymphovascular invasion and a high Ki67 proliferation index, both indicators of aggressive disease. Galleri does not search only for individual mutated DNA fragments. Instead, it analyzes genome-wide methylation patterns at thousands of informative CpG sites, which the authors say can produce a detectable signal even when mutant allele fractions are extremely low. They also cite previous work suggesting that circulating tumor allele fraction is a stronger predictor of classifier performance than absolute ctDNA concentration or clinical stage alone.

The authors further contend that Galleri preferentially identifies tumors with a likelihood of causing harm rather than indiscriminately detecting every small growth. In substudy 3 of the Circulating Cell-free Genome Atlas, five-year survival among participants whose tumors were detected by Galleri was comparable to survival among people whose cancers were found through conventional clinical pathways. Participants whose tumors were not detected by the test generally had significantly better five-year overall survival than those whose tumors were detected. These observations are consistent with a test that tends to find biologically consequential cancers, although the correspondence does not present them as proof that Galleri can predict whether every individual tumor will become dangerous.

Diagnostic sensitivity in the early CCGA substudy rose with stage: 16.8% for stage I cancer, 40.4% for stage II, 77.0% for stage III and 90.1% for stage IV, with the respective 95% confidence intervals reported in the article. More recent prospective results came from PATHFINDER 2, in which slightly more than half of newly diagnosed cancers were found at stage I or II and about 70% at stages I through III. Nearly three-quarters of cancers detected by Galleri in that study occurred in cancer types without an existing recommended screening program. For 12 aggressive cancers accounting for roughly two-thirds of US cancer deaths, episode sensitivity reached 70%. NHS-Galleri produced results the authors describe as similar, reinforcing the evidence that the test can supplement screening for cancers for which routine population screening is unavailable.

Those results must be considered alongside the unsuccessful primary endpoint in NHS-Galleri. The trial did not find a statistically significant reduction in combined stage III and IV diagnoses among 12 prespecified cancers. Nevertheless, the authors report several secondary findings after three screening rounds: a 16% increase in stage I and II diagnoses, a reduction of more than 20% in metastatic diagnoses after rounds two and three, a fourfold increase in screen-detected cancers and a 21% reduction in diagnoses made during emergency presentation. Galleri detected 366 stage I or II cancers, compared with 290 cancers of all stages found through standard-of-care screening alone. These are observed trial outcomes associated with adding Galleri to standard screening, but they do not establish that the test reduced cancer mortality.

The correspondence disputes the view that the absence of a demonstrated mortality benefit makes a screening test clinically ineffective. It argues that clinical utility can also include earlier diagnosis, a greater opportunity for curative treatment, fewer metastatic presentations, more efficient diagnostic evaluation and reduced reliance on emergency care. The authors note that screening technologies have often been implemented through gradual evidence generation before definitive mortality benefits were available. They cite the recently reported NordICC colonoscopy trial as an example of a screening method that had not demonstrated a mortality benefit after 13 years of follow-up, although colonoscopy remains an accepted standard in the United States. Even so, NHS-Galleri was neither designed nor statistically powered to establish mortality reduction, making a definitive answer dependent on larger samples and longer follow-up.

The authors also reject the characterization of reductions in stage IV disease as merely a migration from one advanced stage to another. They point to improved five-year survival across US cancers, now exceeding 70%, with particularly large gains among patients diagnosed at regional stage. From their perspective, the clinically important distinction is whether a cancer is identified before it becomes metastatic, rather than relying on a simple division between early and late disease. The NHS-Galleri findings are consistent with that interpretation because metastatic diagnoses fell while earlier-stage diagnoses increased. The trial results nevertheless need longer follow-up to determine whether those shifts translate into lower cancer-specific deaths.

Prospective evidence provides a separate answer to concerns about false positives and procedural harm. PATHFINDER 2 reported a false-positive rate of 0.36%, a positive predictive value of 60%, cancer signal-of-origin accuracy of 91.7% and a median time to diagnostic resolution of 47 days. Fewer than 1% of participants underwent an invasive diagnostic procedure, and serious study-related adverse events were few. NHS-Galleri reported a false-positive rate of 0.45%, a positive predictive value of 58% and signal-of-origin accuracy of 92.5%, again with few serious study-related adverse events. Anxiety measured with validated instruments rose only mildly and transiently, returning to baseline within 12 months. The authors also cite an FDA advisory committee vote of 10–0 in favor of the test’s safety profile, while the present correspondence remains an argument by the test’s developers and does not substitute for independent regulatory review.

False negatives are interpreted as a limitation of Galleri’s intended role as an addition to, rather than a replacement for, established screening. A negative “No Cancer Signal Detected” result does not rule out cancer or justify discontinaging guideline-recommended screening. The authors say available observations do not support claims that a negative result reduces adherence: PATHFINDER 2 found no reduction at 12 months in colorectal, cervical, breast or lung cancer screening adherence, while real-world evidence found no reduction in mammography use during the 24 months after a negative result. PATHFINDER 2 also detected 91 cancers through standard screening and another 85 through routine care prompted by symptoms or incidental findings. NHS-Galleri separately detected 236 cancers through standard screening within its intervention arm, illustrating how the tests are intended to operate as complementary pathways.

Health-economic findings remain model-based rather than observed savings from the trial. Analyses cited in the correspondence estimate that Galleri used alongside standard care may be cost-effective over a lifetime horizon when changes in cancer stage, treatment intensity and diagnostic pathways are included, with the most favorable results when the high costs of advanced cancer care are incorporated. A separate model estimated that annual screening of approximately 13 million eligible people in England would increase colonoscopy demand by 2.09% and CT use by 0.76%, equivalent to about 1,040 additional colonoscopies and 4,720 CT examinations per million people screened each year. The correspondence also corrects the characterization of the Nancy Gardner Sewell Medicare MCED Screening Coverage Act: rather than mandating coverage, it creates a Medicare benefit category and gives the Centers for Medicare & Medicaid Services authority to apply its standard evidence-based review process. Taken together, the authors argue that continued evaluation is more justified than categorical dismissal, while mortality outcomes remain the unresolved question.

Subject of Research: Clinical and economic evidence for the Galleri multi-cancer early detection blood test

Article Title: Rebuttal to “Early Warnings About the Galleri Test Were Disregarded”

Article References: Klein, E. A., Venn, O., & Fung, E. T. (2026). Rebuttal to “Early Warnings About the Galleri Test Were Disregarded”. Clinical Proteomics, 23(1), Article 51. https://doi.org/10.1186/s12014-026-09644-x

Image Credits: AI Generated

DOI: 10.1186/s12014-026-09644-x

Keywords: Galleri, multi-cancer early detection, cancer screening, liquid biopsy, ctDNA, NHS-Galleri, PATHFINDER 2, false-positive rate, stage shift, cancer mortality, Rebuttal, Early

The research team, led by Mohammad Rehan Asad of Majmaah University in Saudi Arabia and Atta Ullah Khan of the University of Campania Luigi Vanvitelli in Italy, systematically reviewed eight studies encompassing 325 patients with HPV-negative head and neck squamous cell carcinoma. Their findings are striking: patients with detectable postoperative ctDNA faced a pooled hazard ratio of 10.07 for diminished recurrence-free survival, meaning they experienced roughly a ten-fold elevated risk of cancer returning compared to those whose blood showed no trace of tumor DNA. The association extended to overall survival as well, with a pooled hazard ratio of 8.98, suggesting that ctDNA positivity may influence mortality through mechanisms beyond recurrence alone.

Head and neck squamous cell carcinoma is the seventh most common malignancy worldwide, accounting for approximately 890,000 new cases annually. While human papillomavirus drives a subset of oropharyngeal cancers, the majority of HNSCC cases remain HPV-negative, predominantly linked to tobacco and alcohol consumption. These HPV-negative tumors carry a poorer prognosis than their HPV-positive counterparts, and despite advances in multimodal treatment, disease recurrence occurs in 50 to 60 percent of patients following curative-intent treatment, with most relapses occurring within two years. Current surveillance relies on clinical examinations and radiological imaging, which lack the sensitivity to detect microscopic residual disease before it becomes clinically apparent.

Circulating tumor DNA has emerged as a promising liquid biopsy biomarker in precision oncology. While ctDNA utility is well-established in HPV-positive HNSCC, its application in HPV-negative disease presents unique challenges due to genetic heterogeneity and high mutational burden. Recent advances in tumor-informed personalized ctDNA assays using next-generation sequencing and digital droplet PCR have enhanced sensitivity and specificity in non-viral solid tumors. Tumor-informed assays demonstrate superior performance compared to tumor-agnostic approaches, with reported sensitivities exceeding 90 percent and specificities approaching 99 percent. Emerging evidence demonstrates that postoperative ctDNA positivity predicts disease recurrence and inferior survival outcomes in colorectal, breast, and lung cancers, with preliminary studies suggesting similar prognostic value in HPV-negative HNSCC.

The eight included studies employed a remarkable diversity of ctDNA detection architectures, encompassing NGS-based platforms, commercial tumor-informed assays such as Signatera and RaDaR, and emerging pooled methodologies like MAESTRO-Pool. The temporal relationship between surgical intervention and biomarker assessment ranged considerably, from immediate postoperative periods within one to three days to delayed sampling intervals up to three months after surgery. Five of the eight studies used MRD or residual-disease terminology, framing post-treatment ctDNA detection as a minimal residual disease application, while the remaining studies evaluated postoperative ctDNA primarily in the contexts of relapse monitoring, ctDNA clearance, or PET-adjunct surveillance.

Clinical performance among the MRD-focused studies was encouraging but heterogeneous. In the study by Honoré and colleagues, ctDNA was detected in four of 42 evaluable patients within 12 weeks after curative-intent treatment; three of these patients relapsed, and the median lead time before clinical recurrence was 7.0 months. Sim and colleagues reported a positive predictive value of 92.9 percent and a negative predictive value of 80 percent for immediate postoperative ctDNA detection in relation to recurrence or death. Karasik and colleagues reported lower actuarial one-year recurrence-free survival among ctDNA-positive patients at 38.2 percent compared to 87.4 percent among ctDNA-negative patients. In the LIONESS cohort, Flach and colleagues reported 91.3 percent sensitivity, 94.2 percent specificity, 87.5 percent positive predictive value, and 96.1 percent negative predictive value for recurrence detection using plasma samples collected at least 14 days after surgery.

Subgroup stratification by patient cohort composition revealed comparable effect estimates across HPV status representation. Three studies enrolling exclusively HPV-negative populations yielded a pooled hazard ratio of 10.33, while five studies enrolling mixed cohorts including both HPV-negative and HPV-positive patients yielded a pooled hazard ratio of 9.91. Statistical heterogeneity remained negligible within both subgroups, with I² values of 0 percent, suggesting that the observed association between postoperative ctDNA and recurrence-free survival was not substantially influenced by HPV status representation in the study population. Individual study estimates demonstrated uniform directional concordance, ranging from 5.64 to 22.28, with all confidence intervals excluding the null.

However, the researchers urge caution in interpreting these striking effect magnitudes. Leave-one-out sensitivity analysis revealed that sequential omission of individual studies yielded pooled hazard ratios ranging from 2.22 to 2.43, considerably lower than the primary pooled estimate of 10.07. While all sensitivity estimates remained statistically significant, this discrepancy suggests that the magnitude of the primary effect may reflect the combined influence of all eight studies rather than representing a stable, platform-independent association. The observed hazard ratios substantially exceed those reported in other solid tumors, such as colorectal cancer at 2.5 to 4.0 and breast cancer at 2.0 to 3.5, suggesting potential overestimation. Multiple factors may contribute, including heterogeneous detection methodologies with variable sensitivity and specificity, small individual study sample sizes susceptible to selection bias, variable plasma collection timing affecting ctDNA kinetics, and confounding bias in one-third of studies where treatment decisions may have been influenced by ctDNA status.

Publication bias testing with only eight studies has inherent power limitations. While Egger’s regression-based test and Begg’s rank correlation test were non-significant and the funnel plot appeared symmetric, these findings do not definitively exclude bias. The LIONESS trial, using personalized ctDNA assays in predominantly HPV-positive HNSCC, reported a hazard ratio of approximately 2.5, substantially lower than the 10.07 observed here, highlighting the need for comparative studies. Additionally, 62.5 percent of studies enrolled mixed HPV-positive and HPV-negative cohorts, limiting applicability to purely HPV-negative disease. All studies restricted to resectable disease, reducing generalizability to unresectable populations. The small overall sample size of 325 patients, with approximately 180 HPV-negative, constrains statistical power for meaningful subgroup analyses.

The clinical utility of postoperative ctDNA detection for guiding treatment decisions or surveillance strategies in HPV-negative HNSCC remains incompletely established. Until larger, prospective, multi-institutional studies employing standardized methodologies and enrolling purely HPV-negative populations are conducted, postoperative ctDNA detection should be considered an investigational biomarker rather than a clinically validated tool. Randomized controlled trials examining whether ctDNA-guided interventions improve clinical outcomes are essential before recommending routine clinical implementation. Future research should prioritize standardization of detection methodologies and prospective validation in well-characterized HPV-negative HNSCC populations, potentially transforming how clinicians stratify recurrence risk and personalize adjuvant therapy decisions for this challenging malignancy.

Subject of Research: Postoperative ctDNA as a prognostic biomarker for recurrence in HPV-negative head and neck squamous cell carcinoma

Article Title: Postoperative ctDNA could potentially spare patients from unnecessary adjuvant therapy in HPV-negative head and neck squamous cell carcinoma: a meta-analysis

Article References: Asad, M. R., Pusarico, A. F., Reji, N., AlRamadneh, T. N., & Khan, A. U. (2026). Postoperative ctDNA could potentially spare patients from unnecessary adjuvant therapy in HPV-negative head and neck squamous cell carcinoma: a meta-analysis. Frontiers in Oncology, 16, Article 1902328. https://doi.org/10.3389/fonc.2026.1902328

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1902328

Keywords: ctDNA, head and neck cancer, HPV-negative, liquid biopsy, minimal residual disease, meta-analysis, recurrence, adjuvant therapy, Postoperative, potentially, spare, patients

Neoantigens are abnormal protein fragments produced by cancer cells as a consequence of the mutations they carry. Because these molecules do not appear on healthy cells, they are precisely the kind of molecular signatures the immune system can be trained to attack, making them attractive and comparatively safe targets for cancer vaccines and T cell-based therapies. The catch is that every patient’s tumor carries a unique set of mutations, so building a personalized immunotherapy requires first cataloguing which neoantigens are present in that individual’s cancer and finding immune cells capable of reacting to them. Until now, that cataloguing has depended almost entirely on analyzing tumor tissue obtained through biopsy or surgery.

That dependence creates a serious bottleneck in clinical practice. As Andrea Garcia-Garijo, PhD, a postdoctoral fellow and first author of the study, explained, many patients do not have easily accessible tumors, while others are simply not healthy enough to undergo an invasive procedure. A metastatic patient with lesions in the liver, lung, and bone may face repeated biopsies to capture the full diversity of their disease, and each procedure carries risk, cost, and delay. The VHIO team, led by senior author Alena Gros, PhD, group leader of the Tumor Immunology and Immunotherapy Group, reasoned that blood could solve this problem, since dying cancer cells continuously release fragments of their DNA into circulation, carrying with them a molecular record of the tumor’s mutations.

To test the concept, the researchers isolated and sequenced ctDNA from blood samples of six patients with metastatic melanoma, breast cancer, head and neck cancer, or colorectal cancer. From the sequenced mutations, they computationally predicted which would give rise to neoantigens, and then compared that list against the neoantigens identified through standard analysis of tumor tissue from the same patients. The overlap was striking: across all six patients, ctDNA analysis recovered between 63.25 percent and 97.4 percent of the neoantigens detected by conventional tissue-based methods. In other words, a tube of blood captured most of the therapeutic intelligence that a biopsy would have provided.

More remarkably, the blood-based approach also uncovered neoantigens that tissue analysis had missed entirely. This is not a technical fluke but a reflection of tumor biology. Patients with advanced disease harbor tumors in multiple organs, and each lesion can carry its own complement of mutations. A biopsy of a single lesion is therefore a sample of one outpost of a distributed enemy. Blood, by contrast, collects DNA shed from lesions throughout the body, offering a more representative census of the neoantigen landscape. Gros emphasized this point, noting that by accessing the blood, researchers can identify neoantigens present across different tumor lesions, as well as T cells able to recognize them, giving a broader picture of the cancer throughout the body and potentially enabling T-cell therapies that target multiple tumor sites at once, making it harder for the cancer to escape treatment.

The team did not stop at neoantigens. A second pillar of personalized immunotherapy is finding the patient’s own T cells that can react against those neoantigens, since these cells are the raw material for adoptive cell therapies and a key indicator of whether a tumor is immunogenic at all. When the researchers isolated T cells from the blood of the patients, they found that in six of the eight patients studied, circulating T cells recognized and reacted to neoantigens identified through ctDNA analysis, tissue analysis, or both. This demonstrated that the immune component of the personalized therapy equation, not just the tumor component, can be sourced from a peripheral blood sample.

To determine whether the approach could generalize beyond a handful of carefully selected cases, the researchers expanded their analysis to an independent cohort of 69 patients with a wide variety of metastatic solid tumors. Here the picture became more nuanced. ctDNA was detectable in 32 of the 69 patients, or 46.4 percent, suggesting that a blood-based route to neoantigen discovery may be feasible in roughly half of patients with solid tumors. Notably, among the 17 patients with colorectal cancer, ctDNA was detectable in 14, or 82.4 percent, including patients with mismatch repair-deficient tumors, a subtype that accumulates unusually high numbers of mutations, expresses more neoantigens, and is frequently treated with immunotherapies that depend on neoantigen recognition. For precisely the patients most likely to benefit from neoantigen-targeted treatment, the blood-based method appears most reliable.

The study also had its failures, and these are informative in their own right. In two of the initial eight patients, one with breast cancer and one with head and neck cancer, the researchers could not isolate ctDNA at all. Gros explained that this is consistent with the known behavior of some tumors, which shed very little DNA into the bloodstream. Tumor shedding rates vary with tumor type, stage, burden, and biology, meaning that blood-based neoantigen discovery will not be universal. For the substantial fraction of patients in whom ctDNA is detectable, however, the method could complement or even replace tissue analysis, and for patients whose tumors are inaccessible or who cannot tolerate a procedure, it may be the only viable option.

The clinical implications extend beyond the initial design of therapy. Because blood can be drawn repeatedly with minimal burden to the patient, the same approach could be used to track how the neoantigen landscape and the patient’s immune response evolve over the course of treatment. Gros pointed to this as a major opportunity: serial blood sampling could allow clinicians to monitor treatment responses in real time, watch for the emergence of resistant tumor subclones, and adjust therapy as the disease changes. In an era when immunotherapies are increasingly dynamic and combination-based, a monitoring tool that requires only a venipuncture rather than a repeat biopsy could fundamentally change how treatment decisions are made.

There are, of course, important caveats. The initial cohort was small, and certain cancer types were only thinly represented, so the reported detection rates carry wide uncertainty. Gros and her colleagues stress that validation in larger patient cohorts is needed before the approach can be adopted widely in the clinic. The computational pipeline for predicting neoantigens from DNA sequences remains imperfect, and detecting a neoantigen-encoding mutation in ctDNA does not guarantee that every tumor lesion expresses the corresponding protein. Still, the study establishes a proof of principle with a clear quantitative foundation: blood alone can recover the majority of tissue-derived neoantigens, reveal additional ones invisible to biopsy, and supply reactive T cells from the same sample. If larger studies confirm these findings, the biopsy, long the mandatory first step of precision oncology, may find itself sharing that role with something far simpler: a vial of blood.

Subject of Research: Blood-based identification of cancer neoantigens and neoantigen-specific T cells using circulating tumor DNA for personalized immunotherapy

Article Title: Blood could serve as a main source for finding cancer-specific proteins needed to develop personalized treatment

Article References: Blood could serve as a main source for finding cancer-specific proteins needed to develop personalized treatment. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: ctDNA, neoantigens, liquid biopsy, personalized immunotherapy, T cells, metastatic cancer, melanoma, colorectal cancer, Cancer Discovery, tumor mutations, cancer vaccines, Vall d'Hebron Institute of Oncology

The starting point of the review is the physical assault that radiotherapy delivers. Ionizing radiation deposits energy that breaks DNA directly and, indirectly, floods cells with reactive oxygen species that damage proteins, lipids, and genomes alike. The dose, the fractionation schedule, and the type of radiation used all determine the character of this pressure. Cells that survive the initial insult do so by activating their DNA damage response machinery, a coordinated network of sensors, transducers, and effectors that pauses the cell cycle, repairs double-strand breaks through pathways such as non-homologous end joining and homologous recombination, and, when damage is overwhelming, triggers senescence or apoptosis. But the review emphasizes that DNA repair is only the first layer of a much deeper program of tolerance.

That deeper program is cellular plasticity. Rather than dying or fully recovering, a subset of surviving cells appears to enter altered, quasi-stable states that echo phenomena described in drug-treated tumors. The authors catalog several of these: persister-like states in which cells reversibly suspend proliferation; cancer stem cell-like states marked by molecules such as CD44 and aldehyde dehydrogenase, with enhanced self-renewal and repair capacity; senescence-like states, detectable in part by senescence-associated beta-galactosidase, in which cells remain metabolically alive but stop dividing and can secrete inflammatory signals; and hybrid epithelial-mesenchymal transition states that combine adhesive and migratory traits. Crucially, these states are not permanent identities. They are plastic, meaning the same residual cell may drift between them, and that fluidity makes them extraordinarily difficult to eliminate with any single targeted agent.

Alongside chromatin remodeling and transcriptional stress memory, which allow cells to carry a kind of biochemical recollection of the radiation they endured, these plastic states form the tumor-cell-intrinsic half of the radioresistance story. The review is careful to note that this intrinsic component complements rather than replaces classical radiosensitivity, which depends on factors such as oxygenation, cell-cycle phase, and repair capacity. What is new is the recognition that intrinsic tolerance alone cannot explain why recurrences so often emerge in predictable locations and time windows. For that, the authors argue, one must look outward, to the microenvironment that surrounds and stabilizes the surviving cells.

The concept of the tolerant niche is the conceptual heart of the paper. The authors describe several recurring microenvironmental configurations that act as sanctuaries for residual disease. Hypoxic niches are perhaps the best known: low oxygen reduces the radiation-induced free radical chemistry that makes oxygen so potent a radiosensitizer, and hypoxia simultaneously drives stem-like and invasive transcriptional programs. Perivascular niches, the zones around surviving blood vessels, shelter quiescent tumor cells and are rich in protective signaling. Niches dominated by cancer-associated fibroblasts and remodeled extracellular matrix provide both mechanical and biochemical support, secreting growth factors and stiffening tissue architecture in ways that dampen radiation lethality. Metabolic niches, shaped by nutrient scarcity and altered metabolite exchange, and myeloid niches, populated by tumor-associated macrophages, myeloid-derived suppressor cells, and regulatory T cells that suppress antitumor immunity, complete the picture. In each case, the niche does not merely coexist with tolerant cells; it actively maintains their state.

One of the review’s most useful contributions is its insistence that these mechanisms vary substantially among tumor types. The relative weight of hypoxia, stromal shielding, immune suppression, or stem-like plasticity differs between, for example, glioblastoma, pancreatic ductal adenocarcinoma, and lung cancer, and the authors caution against assuming that a strategy validated in one context will transfer to another. This heterogeneity has practical consequences for how the field measures residual disease. The authors assess the tools available and find them strikingly unequal in maturity. Functional imaging, including hypoxia-targeted PET tracers and advanced MRI sequences, and liquid biopsy based on circulating tumor DNA, offer selected clinical readouts that can already be deployed in trials to track residual disease and recurrence risk over time.

Spatial omics technologies, by contrast, which map gene expression and other molecular features across intact tissue sections, currently serve mainly as discovery and validation tools rather than clinical diagnostics. They are indispensable for identifying which cells occupy which niches and how those relationships change after irradiation, but sampling limitations, cost, and analytical complexity keep them out of routine practice. The review is candid about this gap: the field can describe tolerant niches in exquisite detail in resected specimens, yet it largely lacks the longitudinal, minimally invasive measurements needed to watch them form and dissolve in living patients. Bridging that gap, the authors suggest, will require combining serial ctDNA monitoring with imaging and, where feasible, repeat tissue sampling.

On the therapeutic side, the review outlines both evidence-based and investigational strategies for what the authors term niche-informed radiotherapy. Established approaches include hypoxia modification, dose escalation and altered fractionation, and combinations with DNA damage response inhibitors that disable the repair programs tolerant cells rely on. More speculative candidates target the niche itself: agents that reprogram cancer-associated fibroblasts, normalize tumor vasculature, modulate myeloid suppressor cells, or relieve immune suppression so that checkpoint blockade can act on residual disease. Senolytic strategies aimed at clearing senescence-like cells, and agents designed to push plastic persister states out of their protective equilibrium, also feature among the investigational options. The unifying principle is that candidate combinations should be validated against the specific niche dependencies of a given tumor before clinical adaptation, rather than applied indiscriminately.

The authors are equally clear about the obstacles standing between this framework and the clinic. Conceptually, tolerant niches are dynamic and heterogeneous, so static snapshots may mislead. Sampling remains a fundamental problem, since the most informative regions of a treated tumor are often inaccessible. Implementation faces the usual barriers of combination-therapy trials, toxicity management, and the absence of validated biomarkers that identify which patients carry which niche dependencies. None of these limitations, in the authors’ view, undermines the framework; they simply define the work that remains. The review, which was supported by numerous Chinese national and institutional research programs and published open access on 9 October 2026, is intended as a roadmap rather than a final verdict.

If the tolerant niche concept holds up under experimental and clinical scrutiny, its implications for oncology could be considerable. Recurrence after radiotherapy would no longer be viewed as a mysterious resurgence but as the predictable product of a documented sequence: radiation pressure, followed by the emergence of plastic residual states, followed by their stabilization within hypoxic, stromal, metabolic, and immune sanctuaries. Each step in that sequence offers an interception point, a moment when a rationally chosen combination therapy might extinguish the embers before they reignite. Turning that vision into practice will demand the longitudinal monitoring tools and niche-specific combination trials the review calls for, but it reframes one of radiotherapy’s oldest frustrations as a solvable, spatially defined problem in tumor ecology.

Subject of Research: Radioresistance and tumor recurrence through cellular plasticity and radiation-induced tolerant niches in the tumor microenvironment

Article Title: Radioresistance and tumor recurrence: cellular plasticity, tolerant niches, and therapeutic opportunities

Article References: Zhang, Y., Li, H., Lv, S., Peng, L., Meng, W., Guo, J., Lu, Y., Chen, W., Yang, W., & Peng, X. (2026). Radioresistance and tumor recurrence: cellular plasticity, tolerant niches, and therapeutic opportunities. Molecular Cancer. https://doi.org/10.1186/s12943-026-02806-3

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02806-3

Keywords: radioresistance, radiotherapy, tumor recurrence, tolerant niches, cellular plasticity, DNA damage response, tumor microenvironment, cancer stem cells, hypoxia, residual disease, spatial omics, ctDNA

Peter Hosein, M.D., co-leader of Sylvester’s Gastrointestinal Cancer Site Disease Group, called the approval a monumental shift in the treatment of pancreas cancer. The significance lies not only in the survival benefit itself but in what it signals about the future of the disease: pancreatic cancer, long treated as a monolith to be attacked with blunt cytotoxic chemotherapy, is increasingly being understood at the molecular level, allowing drugs designed for specific biological vulnerabilities to be matched with the patients whose tumors carry them. Targeted therapies of this kind have transformed outcomes in lung cancer, breast cancer and leukemia, and daraxonrasib’s success suggests that pancreatic oncology is finally entering that same era of precision medicine.

Even as treatment advances, earlier detection remains the field’s most urgent unmet need, and a new grant from the Pancreatic Cancer Action Network aims to address it. The organization has awarded Sylvester researchers 225,000 dollars over two years to help establish a blood test for pancreatic cancer based on circulating tumor DNA, or ctDNA. For patients with lung cancer, colon cancer and certain other solid tumors, liquid biopsies that detect fragments of tumor DNA shed into the bloodstream have become routine tools, helping oncologists identify molecular weaknesses in a tumor without invasive procedures and adjust treatment as the disease evolves. Pancreatic cancer patients have not enjoyed that advantage; invasive tissue biopsies remain the standard, and the tumors’ biology has made reliable ctDNA detection difficult.

The PanCAN-funded project seeks to change that by establishing ctDNA analysis as a dependable way to measure the molecular makeup of metastatic pancreatic cancer, one of the deadliest malignancies known. If successful, the approach could allow clinicians to track tumor evolution in near real time through simple blood draws, matching patients to targeted agents as new mutations emerge and monitoring treatment response without repeated surgical intervention. The work complements the daraxonrasib story in an important way: targeted therapies are only as useful as the molecular diagnostics that identify eligible patients, and liquid biopsies could dramatically widen the funnel of patients who benefit from drugs like the newly approved pill.

Shifting from treatment to prevention, Sylvester investigators have published sobering new data on alcohol’s role in cancer mortality. A study by the center’s researchers, first presented at the annual meeting of the American Society of Clinical Oncology and now published in The Lancet Regional Health – Americas, found that alcohol-attributable cancer deaths in the United States doubled between 1990 and 2023. Perhaps more striking than the overall trend is its demographic reach. Alcohol-linked cancer deaths are not confined to older adults or to liver cancer, the organs and populations most commonly associated with drinking-related disease in the public imagination.

Among adults aged 20 to 54, the study found that colorectal cancer was the leading alcohol-related cancer death in men, while breast cancer ranked first among women. Those findings carry substantial public health implications, because they indicate that alcohol’s carcinogenic influence operates across a wide swath of tumor types and age groups, and that the burden is falling on populations who may not perceive themselves as being at risk. Alcohol is an established carcinogen, classified as such by international cancer research bodies, and the mechanistic pathways are well described: its metabolite acetaldehyde damages DNA, alcohol consumption impairs nutrient absorption and hormone regulation, and it acts as a solvent that enhances the penetration of other carcinogens into tissues. The doubling of deaths over three decades suggests that awareness and policy responses have not kept pace with the accumulating evidence.

Against that backdrop, a second Sylvester study examined whether communication strategies could close the awareness gap. Writing in Cancer, a journal of the American Cancer Society, researchers led by Taghrid Asfar, M.D., MSPH, professor of public health, reported that online warnings about alcohol and cancer prompted stronger responses when they named specific cancers and included AI-generated images depicting health consequences. Many people remain unaware that alcohol is linked to several cancers, Asfar noted, and the study suggests that specificity matters: generic warnings about harm are less effective than messages that identify concrete diseases and pair that information with vivid visual depictions of what those diseases entail.

The work sits at the intersection of behavioral science and emerging technology, testing whether generative artificial intelligence can be harnessed to produce health communication that is both scalable and persuasive. If AI-generated imagery can meaningfully improve public understanding of alcohol’s cancer risks, health agencies could deploy tailored warning campaigns at low cost across digital platforms, reaching younger audiences precisely where the mortality data show the burden is growing. The approach also raises questions the field will need to address, including how to ensure that synthetic images used in public health messaging remain accurate and non-misleading, but the core finding, that specificity plus visual evidence improves risk comprehension, offers a practical template for campaigns aimed at other preventable risk factors as well.

Artificial intelligence is also reshaping basic discovery at Sylvester, where scientists have used computational methods and advanced laboratory experiments to illuminate a previously hidden corner of the human proteome. The protein universe contains hundreds of millions of members, yet the vast majority remain poorly characterized, a biological darkness that may conceal clues to health and disease. In research published in Nature, the Sylvester team identified a protein that helps cells form physical connections and share resources with one another, revealing an entirely new layer of cellular communication. Daniel Isom, Ph.D., the study’s senior author, said the discovery suggests there is another layer of biology that has been hiding in plain sight.

The finding demonstrates how machine learning can guide experimental biology toward targets that traditional hypothesis-driven research might never have flagged, scanning enormous sequence spaces for proteins with predicted structural features and then validating their functions in the laboratory. Because the newly characterized protein governs how cells connect and exchange resources, it could prove relevant to cancer, where communication between tumor cells and their neighbors shapes growth, survival and drug resistance. Rounding out the center’s recent output, a multicenter study published in Blood Cancer Discovery, conducted with Memorial Sloan Kettering Cancer Center and Moffitt Cancer Center, identified loss of the RHOA gene as a mechanism by which some large B-cell lymphomas evade CAR T-cell therapy, disrupting key immune responses and offering a route toward predicting and overcoming treatment resistance. Meanwhile, Sylvester researcher Melissa Lopez, Ph.D., MS, RDN, nutrition lead in lifestyle medicine at the center’s Survivorship and Supportive Care Institute, received an NCI ENICTO pilot grant to test whether routine clinical and nutritional markers from standard lab results can predict which patients will suffer the heaviest symptom burden during and after chemotherapy, a question that could make the chemotherapy journey more predictable for the many patients for whom it remains anything but uniform. Together, the September and October findings sketch a portrait of a cancer center working simultaneously at the bedside, in the clinic, and deep inside the dark proteome, with each advance feeding the others.

Subject of Research: Recent advances in pancreatic cancer therapy, alcohol-related cancer mortality, ctDNA diagnostics, AI-based protein discovery and CAR T-cell resistance research at Sylvester Comprehensive Cancer Center

Article Title: Sylvester Cancer Tip Sheet for September and October, 2026

Article References: Sylvester Cancer Tip Sheet for September and October, 2026. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: pancreatic cancer, daraxonrasib, FDA approval, targeted therapy, ctDNA, liquid biopsy, alcohol and cancer, artificial intelligence, dark proteome, CAR T-cell therapy, lymphoma, chemotherapy side effects

The central question was deceptively simple: does the amount of tumor DNA floating in a patient’s plasma actually mirror what radiologists see on a scan? The answer, according to the analysis led by Isabel Heidrich, with Klaus Pantel and Christoffer Gebhardt as senior authors, is a qualified yes. Circulating tumor DNA levels rose and fell in broad agreement with disease status, increasing significantly as radiologic response worsened across the standard RECIST 1.1 categories, from complete remission through partial remission and stable disease to progression. The statistical association was modest but real, with a Spearman correlation coefficient of 0.31 and a p-value of 0.002 across 99 paired time points.

Yet the study’s most valuable contribution may be its honest accounting of where that agreement breaks down. When the researchers tested how well a single ctDNA measurement could identify progressive disease, the discriminative performance was only moderate, yielding an area under the receiver operating characteristic curve of 0.69. Threshold analyses exposed a fundamental trade-off that clinicians will recognize immediately. Setting the bar high, at 25 or more mutant molecules per milliliter of plasma, produced strong specificity of at least 83 percent but sensitivity of no more than 30 percent, meaning the test rarely cried wolf but also missed most progressing patients. Lower thresholds of one to two mutant molecules per milliliter hovered around 56 percent for both sensitivity and specificity, a level of accuracy that cannot stand alone.

To move beyond categorical imaging readouts, the team also compared ctDNA concentrations directly with total metastatic tumor volume, calculated quantitatively rather than judged by eye. Here the correlation was stronger: ctDNA levels tracked tumor volume with a Spearman coefficient of 0.46, highly significant at p less than 0.0001 across 73 paired time points. Crucially, timing mattered. When blood draws and imaging occurred within 30 days of each other, the correlation tightened to 0.56, while measurements separated by longer intervals showed weaker agreement. This temporal effect carries a practical lesson for clinical trials and routine care alike: a ctDNA result is most informative about tumor burden when it is anchored closely in time to an imaging reference point.

Perhaps the most striking finding, however, concerned change itself. If ctDNA is a faithful liquid biopsy of tumor dynamics, then a rise or fall in plasma DNA should parallel a corresponding change in tumor volume. It did not. Dynamic changes in ctDNA were not significantly correlated with changes in tumor volume, with a correlation coefficient of just 0.20 and a p-value of 0.25. In other words, a patient whose ctDNA dropped sharply was not reliably the patient whose tumors shrank the most. This decoupling of trajectories suggests that ctDNA shedding is governed by biology that a ruler on a scan cannot see, including cell death rates, vascularization, and the metabolic state of individual metastases.

That spatial dimension emerged forcefully from the organ-specific analyses. The strength of the association between ctDNA and tumor burden varied dramatically depending on where the metastases were located. Lymph node and peritoneal metastases showed comparatively strong relationships between ctDNA levels and disease status, while lung, liver, and brain metastases contributed far less detectable DNA to the bloodstream. This pattern of differential shedding has direct clinical implications: a patient whose disease is confined to visceral sites may have undetectable ctDNA despite substantial tumor burden, while another with bulky nodal disease may show abundant plasma DNA. A negative blood test, the study suggests, cannot be interpreted without knowing the anatomy of the disease it is meant to represent.

The researchers also quantified how often ctDNA dynamics and radiologic assessments actually agreed. Concordance was high among patients whose disease was clearly responding, reaching 85 percent in those with complete or partial remission. In stable or progressive disease, agreement fell to 72.9 percent. The discordant cases, rather than being dismissed as noise, were examined descriptively and linked to three plausible culprits: tumor heterogeneity within and across metastatic sites, differences in the timing between blood draws and scans, and treatment-related factors that may alter shedding independently of tumor cell numbers. Immune checkpoint inhibitors, which unleash immune cells to attack tumors, may cause inflammatory swelling or delayed shrinkage that complicates both imaging and biomarker readouts in the early weeks of therapy.

Technically, the study relied on a UMI-based amplicon next-generation sequencing assay capable of detecting mutations in BRAF, EGFR, KRAS, NRAS, and PIK3CA. Unique molecular identifiers allow the sequencing platform to distinguish true mutant fragments from errors introduced during amplification, a critical safeguard when hunting for a handful of mutant molecules in a sea of healthy cell-free DNA. By quantifying ctDNA as mutant molecules per milliliter rather than as a binary positive-or-negative call, the assay enabled the continuous, high-frequency sampling that made the temporal analyses possible. The retrospective design and the modest cohort size of 42 patients mean the findings should be validated prospectively, but the density of sampling, 241 time points, gives the conclusions a robustness that sparse datasets cannot match.

What emerges from the combined analysis is neither a triumph for liquid biopsy nor a rebuttal of it, but a map of its boundaries. ctDNA clearly reflects radiologic disease status and overall tumor burden, and its correlation with volume strengthens when measurements are temporally aligned. At the same time, the moderate discrimination of progression, the weak link between ctDNA dynamics and volume changes, and the pronounced heterogeneity of shedding across metastatic sites all argue against replacing scans with blood tests. Instead, the authors position ctDNA as a complementary biomarker, one that adds a molecular, real-time layer to the anatomical snapshot provided by CT and MRI. For a disease like advanced melanoma, where immunotherapy can produce deep and durable responses in some lesions while others escape, that layered view may be exactly what clinicians need to catch relapse earlier and tailor treatment with greater confidence.

Subject of Research: Longitudinal ctDNA monitoring and its relationship to radiologic response and tumor volume in advanced melanoma

Article Title: Integrated longitudinal analysis of ctDNA, radiologic response, and tumor volume reveals spatial and temporal heterogeneity in advanced melanoma

Article References: Heidrich, I., Streckenbach, A., Rautmann, C., Freiberg, H., Kött, J., Geidel, G., Rünger, A., Zell, T., Roeper, C., Hansen-Abeck, I., Abeck, F., Schneider, S. W., Smit, D. J., Pantel, K., & Gebhardt, C. (2026). Integrated longitudinal analysis of ctDNA, radiologic response, and tumor volume reveals spatial and temporal heterogeneity in advanced melanoma. Journal of Translational Medicine, 24(1), Article 1199. https://doi.org/10.1186/s12967-026-08899-0

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08899-0

Keywords: ctDNA, liquid biopsy, advanced melanoma, immune checkpoint inhibitors, tumor volume, RECIST, tumor heterogeneity, next-generation sequencing, radiologic response, longitudinal monitoring, metastasis, biomarker

Circulating tumour DNA is exactly what its name suggests: genetic material shed by tumour cells into the bloodstream as cancer cells die and release their contents. Unlike a traditional tissue biopsy, which captures only a single snapshot of a single tumour site, ctDNA offers a minimally invasive, real-time window into the entire tumour burden across the body. Because it can be sampled repeatedly from a simple vial of blood, it has the theoretical potential to reveal whether a treatment is working long before changes become visible on a CT scan or PET image. That matters enormously in advanced breast cancer, where treatment strategies are evolving rapidly but where decisions about when to switch therapies still rest largely on imaging-based assessments such as the RECIST criteria, which measure tumour size on radiographic scans.

To establish whether ctDNA truly delivers on this promise, the Aarhus team conducted a rigorous search of the Medline, Embase and Cochrane databases covering studies published up to February 2025. They registered the review prospectively in PROSPERO and evaluated the quality of each included study using the Quality in Prognosis Studies tool, a standard instrument designed to guard against bias in prognostic research. From the eligible literature, they extracted hazard ratios — statistical measures that describe how much a biomarker changes the risk of an event such as disease progression or death — along with their 95 percent confidence intervals, and then pooled the results using random-effects models, which account for variability between studies.

The headline numbers are compelling. Across studies encompassing 2,586 patients, elevated ctDNA levels measured at the start of treatment were associated with roughly a doubling of the risk of disease progression, with a pooled hazard ratio of 2.0 for progression-free survival. For overall survival, the association was even stronger: among 2,454 patients, high baseline ctDNA carried a pooled hazard ratio of 2.6, meaning those patients faced more than two and a half times the risk of death compared with patients whose baseline ctDNA was low. In practical terms, a patient walking into the clinic with abundant tumour DNA in her plasma is statistically likely to fare worse than a patient with barely detectable levels, regardless of the treatment she ultimately receives.

Perhaps even more clinically meaningful is what happens to ctDNA during therapy. The meta-analysis found that unfavourable changes in ctDNA levels over the course of treatment — rising concentrations, or a failure to clear the biomarker once therapy begins — were associated with reduced progression-free survival, with a pooled hazard ratio of 2.5 across 710 patients, and reduced overall survival, with a pooled hazard ratio of 2.4 across 154 patients. This dynamic dimension is where ctDNA distinguishes itself from static prognostic markers. A single measurement tells you something about tumour burden; a series of measurements tells you whether the tumour is responding to the drug in real time. In the era of targeted therapies such as CDK4/6 inhibitors and PI3K inhibitors, where treatment sequences are complex and expensive, an early molecular signal of failure could spare patients months of ineffective therapy and its side effects.

The review also examined whether specific genetic alterations detected in ctDNA carry prognostic information of their own. The answer, broadly, is yes — but with caveats. Mutations in genes such as ESR1, the oestrogen receptor gene that frequently evolves resistance to endocrine therapy, and PIK3CA and TP53, both central players in breast cancer biology, were generally associated with less favourable outcomes when detected at baseline. Studies tracking ESR1 mutations in patients treated with fulvestrant and CDK4/6 inhibitors, for example, have repeatedly shown that the emergence of these mutations in plasma heralds clinical progression. However, the authors note that results across the literature were not entirely consistent, reflecting differences in assay methods, patient populations, treatment contexts and the specific variants analysed. The heterogeneity is a reminder that ctDNA is not a single test but a family of technologies, ranging from digital droplet PCR, which hunts for known mutations with exquisite sensitivity, to whole-exome and whole-genome sequencing, which survey the tumour genome more broadly.

Methodologically, the Danish analysis stands out for its scale and discipline. Sixty-four studies is a large evidence base for a prognostic biomarker review, and the use of the QUIPS tool for quality assessment, together with random-effects meta-analysis and formal measures of statistical heterogeneity, follows the highest standards in the field, including the PRISMA 2020 reporting guidelines. The authors also situate their work within a rapidly moving landscape: clinical guidelines from the American Society of Clinical Oncology now recommend testing for ESR1 mutations to guide therapy in hormone receptor-positive metastatic disease, and proposals for ctDNA-based response criteria — sometimes dubbed ctDNA-RECIST — are actively being developed to complement, and perhaps eventually rival, traditional imaging endpoints.

Still, the researchers are careful about what their findings do and do not establish. A strong prognostic association — showing that ctDNA levels predict outcomes — is not the same as demonstrated clinical utility, meaning proof that acting on the biomarker actually improves patients’ lives. That distinction, long emphasised in the biomarker literature, requires prospective interventional trials in which treatment decisions are randomised based on ctDNA results. The review also highlights gaps in the evidence: overall survival data for dynamic ctDNA changes rest on relatively few patients, subgroup analyses by breast cancer subtype were limited by inconsistent reporting, and the field lacks standardisation in how ctDNA is quantified and what thresholds define ‘elevated’ or ‘unfavourable’ change. Until those issues are resolved, ctDNA remains a powerful prognostic signal rather than a validated decision-making tool for every patient.

Even so, the trajectory is unmistakable. The pooled effect sizes reported here — hazard ratios of 2.0 to 2.6 across thousands of patients — place ctDNA among the most robust prognostic biomarkers described in advanced breast cancer. Combined with the growing arsenal of therapies that can be matched to specific mutations found in plasma, the technology points toward a future in which a blood test drawn at diagnosis and repeated throughout treatment provides oncologists with a continuous, molecular readout of the disease. For patients with advanced breast cancer, whose options depend on catching treatment failure early, that future cannot come soon enough. The Danish team’s synthesis does not close the chapter on ctDNA, but it firmly establishes the scientific foundation on which the next generation of trials — and, ultimately, clinical practice — will be built.

Subject of Research: Prognostic value of circulating tumour DNA in advanced breast cancer

Article Title: Circulating tumour DNA and its clinical relevance in predicting progression-free survival and overall survival in patients with advanced breast cancer: a systematic review and meta-analysis

Article References: Ottosen, C., Kragelund, E., Pedersen, M. A., Nguyen, V. Q., Khan, S. K., Larsen, H. B., Møller, A. L., Gamborg-Kvist, S. H., Spindler, K.-L. G., Brems-Eskildsen, A. S., & Callesen, L. B. (2026). Circulating tumour DNA and its clinical relevance in predicting progression-free survival and overall survival in patients with advanced breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 219(3), Article 23. https://doi.org/10.1007/s10549-026-08087-0

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08087-0

Keywords: ctDNA, advanced breast cancer, liquid biopsy, progression-free survival, overall survival, meta-analysis, biomarkers, ESR1 mutations, systematic review, prognosis, precision oncology, treatment monitoring

The appeal of electrochemical detection lies in its fundamental physics. Rather than relying on bulky optics or fluorescence microscopy, these sensors measure currents, voltages, or impedance changes at an electrode surface when a target molecule binds to a recognition element immobilized there. Amperometric readouts track the flow of electrons generated by redox reactions, potentiometric schemes register voltage shifts at equilibrium, and impedance-based approaches detect how a captured cell or DNA strand alters the electrical resistance at the interface. The result is instrumentation that can be miniaturized to the size of a credit card, manufactured at low cost, and operated by a smartphone, exactly the profile needed for point-of-care testing in clinics and, eventually, at home.

One of the most consequential insights highlighted in the review concerns a biological blind spot in conventional CTC capture. Most commercial platforms rely on antibodies against EpCAM, an epithelial cell surface protein abundant on many tumor cells. Yet tumors do not stand still. During epithelial–mesenchymal transition, or EMT, cancer cells suppress epithelial markers like EpCAM and adopt mesenchymal traits that make them more motile, more invasive, and far more likely to seed metastases. The very cells that matter most for prognosis are the ones that EpCAM-based systems miss. The review emphasizes next-generation sensing strategies specifically designed to catch EMT-associated phenotypes, using panels of aptamers and antibodies directed at mesenchymal and stem cell markers, deformability-based microfluidic separation, and dual-recognition schemes that require multiple binding events to confirm a cell’s identity.

Behind every successful biosensor stands a carefully engineered electrode surface. Nanomaterials have transformed this field by multiplying the effective area available for molecular recognition and by accelerating electron transfer. Gold nanoparticles, graphene and its derivatives, carbon nanotubes, MXenes, and metal–organic frameworks have all been deployed to decorate electrodes with conductive, high-surface-area architectures. Three-dimensional printed graphene-coated electrodes have pushed detection limits toward the single-molecule regime, while silicon nanowire arrays have achieved supersensitive quantification of ctDNA. Conducting polymers add another layer of control, allowing researchers to build biocompatible, antifouling films that keep blood proteins from swamping the signal.

Molecular recognition itself is undergoing a quiet revolution. Antibodies remain workhorses, but aptamers, short synthetic strands of DNA or RNA selected through systematic evolution of ligands by exponential enrichment, offer chemical stability, easy modification, and the ability to bind targets as diverse as whole cells, proteins, and specific mutation-bearing DNA sequences. DNA frameworks and nanostructures can now present aptamers in engineered arrays that remain stable in flowing blood, dramatically improving capture efficiency for heterogeneous CTC populations. The review also surveys dual-aptamer and antibody-aptamer combinations that crosslink target cells to electrode surfaces with far greater specificity than any single binder could achieve.

Scarcity of target demands signal amplification, and the review devotes detailed attention to the molecular machines that provide it. Rolling circle amplification uses a circular DNA template and a strand-displacing polymerase to generate long, repetitive products that carry hundreds of detectable tags. Terminal deoxynucleotidyl transferase-mediated polymerization extends probe strands with long tails of signaling molecules. Perhaps most striking are DNA nanomachines, including bipedal and multipedal DNA walkers that traverse electrode surfaces, catalytically cleaving or assembling reporter strands as they go, converting a single binding event into a cascade of electrochemical signals. Coupled with hybridization chain reactions and catalytic hairpin assembly, these enzyme-free cascades can push limits of detection into the attomolar range without any thermal cycling equipment.

Integration with microfluidics is what turns these chemistries into usable devices. Chips that generate microvortices, spiral channels that sort cells by deformability, and hydrodynamic plasma separators can process milliliters of whole blood in minutes, concentrating targets before they reach the sensing electrode. The review describes electromicrofluidic devices in which captured cells can be gently released under controlled chemical conditions, enabling downstream culture and molecular analysis rather than destructive detection alone. Some platforms now measure PD-L1 expression on captured CTCs without reagents, offering a window into whether a patient is likely to respond to immune checkpoint inhibitors, a decision that traditionally requires tissue that may be inaccessible.

The digital layer is where the field is accelerating fastest. Smartphone-based potentiostats have already demonstrated clinical-grade microRNA and biomarker detection with cloud connectivity, while internet-of-things-enabled embedded potentiostats stream electrochemical data directly to remote servers. Artificial intelligence is being applied at every level, from deep learning models that identify CTCs in complex backgrounds to machine learning classifiers that read ion current fingerprints of individual cells. The review highlights federated learning as a particularly promising framework, allowing algorithms to be trained across multiple hospitals without patient data ever leaving the institution, addressing both the statistical hunger of AI models and the privacy constraints of clinical medicine.

None of this means the technology is ready for prime time without confronting hard problems. Sensor fouling by serum proteins, interference from the staggeringly complex matrix of whole blood, batch-to-batch variability in electrode fabrication, and the dearth of large-scale clinical validation studies all stand between impressive prototypes and regulatory approval. Antifouling surface chemistries, ratiometric electrochemical methods that reference signals internally to improve reproducibility, and ISO-compliant standardization frameworks are among the emerging solutions the authors outline. The translational history of point-of-care biosensing in other diseases suggests these hurdles are surmountable, but they demand sustained collaboration between engineers, clinicians, and regulators.

What emerges from this synthesis is a picture of a field approaching an inflection point. The individual components, nanomaterial-enhanced electrodes, smart aptamers, enzymatic and DNA-based amplification, microfluidic sample preparation, and AI-driven analytics, have each matured considerably. The remaining challenge, and the central thesis of the review, is architectural: weaving them into integrated, validated, sample-to-answer systems that can monitor CTCs and ctDNA continuously, affordably, and accurately. If that integration succeeds, the era in which cancer is tracked through a routine blood draw, with treatment adjusted as the tumor’s molecular signature shifts, moves from promise to practice.

Subject of Research: Electrochemical biosensors for detecting circulating tumor cells and circulating tumor DNA in liquid biopsy

Article Title: Electrochemical Biosensors for Circulating Tumor Cells and ctDNA: Emerging Strategies for Precision Oncology

Article References: Ören Varol, T., & Varol, M. (2026). Electrochemical Biosensors for Circulating Tumor Cells and ctDNA: Emerging Strategies for Precision Oncology. Annals of Biomedical Engineering. https://doi.org/10.1007/s10439-026-04396-z

Image Credits: AI Generated

DOI: 10.1007/s10439-026-04396-z

Keywords: electrochemical biosensors, circulating tumor cells, ctDNA, liquid biopsy, precision oncology, aptamers, nanomaterials, DNA nanomachines, microfluidics, point-of-care testing, EMT, artificial intelligence

The clinical stakes could hardly be higher. Locally advanced rectal cancer has traditionally been treated with neoadjuvant chemoradiotherapy followed by surgery, an approach that saves lives but often exacts a heavy toll, including permanent colostomies, radiation-related bowel dysfunction, urinary problems, and sexual health consequences. Total neoadjuvant therapy (TNT), which delivers chemotherapy and radiation before any operation, has improved outcomes and opened the door to organ preservation for patients whose tumors vanish completely. The TORCH trial took this concept further by adding immunotherapy to the neoadjuvant regimen, creating immunotherapy-based total neoadjuvant therapy, or iTNT, for MSS patients who would typically be excluded from immunotherapy-based strategies because their tumors lack the microsatellite instability that makes them immunotherapy-sensitive.

In the new study, the research team analyzed clinical and genetic data from 63 patients enrolled in the prospectively registered TORCH trial between May 1, 2021, and September 15, 2022. The investigators collected baseline tissue mutations, magnetic resonance tumor regression grade (mrTRG) scores from treatment-time MRI scans, and circulating tumor DNA (ctDNA) positivity measured at multiple points across the treatment course. Their goal was twofold: first, to determine which features measured before, during, or after iTNT best distinguished patients who achieved a complete response from those who did not, and second, to identify early markers of recurrence risk that could guide follow-up intensity and decisions about whether surgery could be safely avoided.

The genetic findings were striking. A baseline mutation in the SMAD4 gene, a well-known tumor suppressor involved in the TGF-beta signaling pathway that helps regulate cell growth and tissue architecture, was significantly associated with poor response to iTNT, with the association reaching statistical significance at P equals 0.007. Patients carrying SMAD4 mutations were markedly less likely to achieve a complete response, suggesting that this single genetic alteration encodes a fundamental resistance to the combined chemo-radiation-immunotherapy approach. The finding aligns with a growing body of evidence that SMAD4 loss reshapes the tumor microenvironment in ways that blunt immune attack and may drive more aggressive, metastasis-prone biology.

Beyond SMAD4, three additional features correlated with complete response rates: post-treatment mrTRG assessed on MRI (P less than 0.0001), tumor mutational burden, or TMB, which quantifies the number of mutations carried by the tumor (P equals 0.03), and the latest ctDNA status, a measure of whether fragments of tumor DNA were still detectable in the bloodstream after treatment (P equals 0.03). TMB is a classic immunotherapy biomarker, since tumors with more mutations tend to produce more neoantigens that the immune system can recognize, but its relevance in MSS rectal cancer treated with combination iTNT had been uncertain. The ctDNA measurement, meanwhile, represents the concept of a liquid biopsy: rather than sampling the tumor itself, clinicians can track fragments of tumor-derived DNA shed into circulation, gaining a real-time view of residual disease that imaging may miss.

The true advance, however, came when the researchers integrated these features into multivariable models. A model combining post-treatment mrTRG, SMAD4 mutation status, TMB, and latest ctDNA status achieved an area under the curve, or AUC, of 0.92 for discriminating complete responders from non-responders, compared with just 0.75 for a model based on mrTRG alone, a statistically significant improvement (P equals 0.0098). An AUC of 0.92 reflects excellent discriminative accuracy, while 0.75 represents only modest performance, so the jump is clinically meaningful. Importantly, the researchers also tested whether prediction could happen earlier in the treatment course. An early integrated model that used mid-iTNT mrTRG along with the genetic features achieved an AUC of 0.89 versus 0.76 for the mrTRG-only model (P equals 0.047), meaning clinicians might one day gauge a patient’s trajectory partway through therapy rather than waiting until the end.

The prognostic analysis added another layer of clinical utility. Using Cox proportional hazards regression and Kaplan-Meier survival analyses, the team found that baseline SMAD4 mutations and ctDNA positivity at later time points were both correlated with an increased risk of disease progression, including local recurrence and distant metastasis. In practical terms, a patient whose blood still shows molecular traces of tumor after treatment completion, or whose original tumor carried a SMAD4 mutation, faces a higher probability that the cancer will return, even if standard assessments look favorable. This kind of molecular residual disease detection is becoming one of the most actively pursued frontiers in oncology, because it can flag recurrence months or even years before radiographic evidence appears, when intervention may be most effective.

The implications for treatment strategy are substantial. For patients with locally advanced rectal cancer, the decision of whether to proceed to surgery or pursue nonoperative management, sometimes called watch and wait, hinges on the confidence with which a complete response can be established. Current assessments rely on a patchwork of digital rectal examination, endoscopy, MRI, and serum markers such as carcinoembryonic antigen, none of which is perfectly reliable. A molecular framework that adds SMAD4 status and serial ctDNA to the mix could give clinicians the confidence to safely spare surgery in true complete responders, while identifying poor responders early enough to intensify their therapy, enroll them in alternative trials, or avoid prolonging an ineffective course of immunotherapy. The study’s authors emphasize that these models are best understood as complementary risk stratification tools rather than standalone decision instruments, augmenting rather than replacing clinical judgment and imaging.

It is worth underscoring what makes the MSS population such an important target. Roughly the overwhelming majority of colorectal cancers are microsatellite stable, and for years, immune checkpoint inhibitors were considered largely futile in this group. The TORCH trial’s demonstration that adding immunotherapy to total neoadjuvant therapy can produce promising complete response rates in MSS patients was itself a paradigm-shifting result, and the current analysis addresses the critical next question: how do we know who is benefiting? Without reliable biomarkers, the field risks either overtreating patients who will never respond or undertreating those who would have responded with more time. The integrated models described here offer a data-driven way to navigate that uncertainty, converting a one-size-fits-all regimen into something closer to adaptive, biology-informed care.

Limitations remain, as they do in any single-trial biomarker analysis of 63 patients. The findings will need validation in larger, independent cohorts, and the logistics of serial ctDNA monitoring, including assay standardization, cost, and the optimal sampling schedule, remain active areas of investigation. The trial was registered as NCT04518280, and the analysis was funded by the National Natural Science Foundation of China and the Beijing Xisike Clinical Oncology Research Foundation. Still, the convergence of tissue genomics, liquid biopsy, and quantitative imaging in a prospectively registered trial represents a template for how biomarker-driven personalization should be developed in rectal cancer. If validated, the combination of SMAD4 mutation status, tumor mutational burden, serial ctDNA tracking, and mrTRG assessment could become a standard part of the decision-making toolkit for MSS locally advanced rectal cancer, helping more patients keep their organs, avoid futile toxicity, and face their disease with a clearer, molecularly grounded picture of what lies ahead.

Subject of Research: Predicting response and prognosis of immunotherapy-based total neoadjuvant therapy in microsatellite stable locally advanced rectal cancer using genetic features and serial circulating tumor DNA

Article Title: Application of genetic features and serial ctDNA in estimating response and prognosis of immunotherapy-based total neoadjuvant therapy (iTNT) for microsatellite stable locally advanced rectal cancer: data from TORCH trial

Article References: Wang, Y., Xu, Y., Lin, Y., Liu, Y., Jing, Q., Shen, L., Wan, J., Wang, Y., Zhang, H., Wu, R., Zhou, S., Chen, Y., Zhang, Z., Wang, J., Sun, Y., Bao, H., Ou, Q., Bao, H., Shao, Y., … Xia, F. (2026). Application of genetic features and serial ctDNA in estimating response and prognosis of immunotherapy-based total neoadjuvant therapy (iTNT) for microsatellite stable locally advanced rectal cancer: data from TORCH trial. Genome Medicine. https://doi.org/10.1186/s13073-026-01755-2

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01755-2

Keywords: rectal cancer, immunotherapy, ctDNA, SMAD4 mutation, tumor mutational burden, total neoadjuvant therapy, microsatellite stable, TORCH trial, liquid biopsy, organ preservation, prognosis, complete response